Generic Products Portfolio
Various
Approved/CommercialMarketed
Key Facts
About Celon Pharma
Celon Pharma is a publicly traded, integrated pharmaceutical company based in Poland, with a strong focus on research and development. It employs over 160 scientists and leverages revenue from its generic drug portfolio to fund innovative drug discovery programs targeting cancers, neurological diseases, and metabolic disorders. The company's strategic direction includes partnerships, such as the collaboration with Tang Capital to establish Novohale Therapeutics, to advance its pipeline.
View full company profileTherapeutic Areas
Other Various Drugs
| Drug | Company | Phase |
|---|---|---|
| Biosimilar Programs | Richter Gedeon | Phase 3 |
| Oligonucleotide APIs | Bachem | Clinical/Commercial |
| Novel Plasma-derived Therapies | Tiantan Bio | Pre-clinical |
| Complex Injectable Generics Pipeline | Amphastar Pharmaceuticals | ANDA Filed / Development |
| Generic Portfolio | Strides Pharma | Approved |
| New Product Launches | FDC India | Development/Filing |
| New Generic Filings (e.g., for US/EU) | Bliss GVS Pharma | Regulatory Review |
| Pipeline of Complex Generics | Mayne Pharma Group | Development |
| Bag APIs | ChemWerth | Approved |
| Oral APIs | ChemWerth | Approved |